Kiadis Pharma Revenue and Competitors

Amsterdam, NH Netherlands

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Kiadis Pharma's estimated annual revenue is currently $7M per year.(i)
  • Kiadis Pharma's estimated revenue per employee is $155,000

Employee Data

  • Kiadis Pharma has 45 Employees.(i)
  • Kiadis Pharma grew their employee count by -34% last year.

Kiadis Pharma's People

NameTitleEmail/Phone
1
Head Pharmacovigilance and SafetyReveal Email/Phone
2
Head Discovery and Pre-clinical DevelopmentReveal Email/Phone
3
Associate Director Clinical OperationsReveal Email/Phone
4
Chief Scientific OfficerReveal Email/Phone
5
Director Process DevelopmentReveal Email/Phone
6
Director FinanceReveal Email/Phone
7
Sr. QA OfficerReveal Email/Phone
8
Lab Manager & Senior Associate Scientist ADReveal Email/Phone
9
Senior Manager Clinical OperationsReveal Email/Phone
10
Senior Data ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$10.5M681%N/AN/A
#2
$4.3M284%N/AN/A
#3
$2M138%N/AN/A
#4
$1.1M70%N/AN/A
#5
$3.7M24-11%N/AN/A
#6
$1.1M70%N/AN/A
#7
$45.3M292-9%N/AN/A
#8
$1.4M90%N/AN/A
#9
$2M138%N/AN/A
#10
$7M45-34%N/AN/A
Add Company

What Is Kiadis Pharma?

Kiadis Pharma is a clinical stage biopharmaceutical company focused on research, development and future commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. Kiadis Pharma is committed to developing innovative and potentially life'saving therapies for patients with late-stage blood cancers and patients with inherited blood disorders, who are in need of a transplant, an area of significant unmet medical need.

keywords:N/A

N/A

Total Funding

45

Number of Employees

$7M

Revenue (est)

-34%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Kiadis Pharma News

2022-04-17 - Natural Killer (NK) Cell Therapeutics Market to See Generated ...

Kiadis Pharma; Cytovia Therapeutics; Nkarta, Inc; Fate Therapeutics; EMERcell; Glycostem; Phio Pharmaceuticals, Innate Pharma, Inc...

2022-04-17 - Acute Lymphocytic/Lymphoblastic Leukemia (ALL ...

... Kiadis Pharma; OBI Pharma; Astellas Pharma Inc. and Medexus Pharma, Inc. Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics...

2022-04-17 - Alpha Thalassemia Market Size, Share, Forecast 2022-2029 ...

Bluebird Bio; Novartis; Kiadis Pharma; Acceleron Pharma. Alpha Thalassemia Market Breakdown by Type: Iron Chelating Drugs; Gene Therapy.

2021-05-14 - KIADIS PHARMA N.V. Kiadis Pharma N : - Notice of Annual General Meeting of Shareholders

Amsterdam, The Netherlands - Kiadis Pharma N.V. ('Kiadis Pharma' or the 'Company') (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, announces that its Annual General Meeting of shareholders ('AGM') will be held at 15:00 CEST on 28 June 2021. Pursuant to tempor ...

2021-05-13 - Notice of Annual General Meeting of Shareholders

Amsterdam, The Netherlands, 13 May 2021 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces that its Annual General Meeting of shareholders ("AGM”) will be held at 15:00 CEST on 28 June 2021. ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.5M45-25%N/A
#2
$7.4M45-2%N/A
#3
$7.7M46-22%N/A
#4
$7.7M46-13%N/A
#5
$5.3M46-19%N/A